---
document_datetime: 2023-09-21 21:16:12
document_pages: 36
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/combivir-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: combivir-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 20.7055033
conversion_datetime: 2025-12-22 11:08:30.613127
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Combivir

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                          | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                                                                                                                      |
|----------------------|------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/1532              | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation | 11/08/2022                          |                                             | SmPC and PL                      | To update sections 4.4 and 4.6 of the SmPC and section 2 of the PL to implement the recommendation of the CHMP to remove the disease information relating to sexual transmission of HIV and to amend the sections related to breast-feeding. |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| IG/1504            | A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release                                                                                                                                                                                                                                                                                                                                         | 20/07/2022   |     | Annex II and PL                  |                                                                                                                                                                                                                                                                                                                                                                                            |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-----|----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0106            | B.II.c.1.c - Change in the specification parameters and/or limits of an excipient - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter)                                                                                                                                                                                                                                                                                | 14/07/2022   | n/a |                                  |                                                                                                                                                                                                                                                                                                                                                                                            |
| PSUSA/9207/ 202111 | Periodic Safety Update EU Single assessment - lamivudine (HIV infections), lamivudine / zidovudine                                                                                                                                                                                                                                                                                                                                                                 | 07/07/2022   | n/a |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                          |
| IG/1425/G          | This was an application for a group of variations. B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer | 31/03/2022   | n/a |                                  |                                                                                                                                                                                                                                                                                                                                                                                            |
| WS/2163            | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of section 5.2 of the SmPC in order to add new information on the elimination half-life of lamivudine, based on final results from studies                                                                                                                                                                    | 16/12/2021   |     | SmPC, Annex II, Labelling and PL | The CHMP considered results from pharmacokinetic studies 204993 and 204994 with an optimal sampling scheme (until 72 hours post-dose), the bioanalytical methods used, the fasted conditions in these studies and the lack of pharmacokinetic interaction between dolutegravir and lamivudine and between lamivudine and abacavir or zidovudine. Overall, the CHMP concluded that the data |

<div style=\"page-break-after: always\"></div>

|         | 204993 and 204994. Study 204993 was a phase I, relative oral bioavailability study of different fixed dose combinations of dolutegravir and lamivudine in healthy subjects. Study 204994 was an open-label, randomized, single dose, crossover, bioequivalence study of fixed-dose combination tablet(s) of dolutegravir and lamivudine versus dolutegravir and lamivudine single entities and food effect assessment in healthy volunteers. In addition, the MAH took the opportunity to bring the PI in line with the latest QRD template version 10.2 and to introduce minor editorial changes. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   |            |            |             | reviewed indicated a terminal elimination half-life for lamivudine of 18-19 hours.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/1990 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of sections 4.2, 4.4 and 5.2 of the SmPC of the fixed-dose combination products Combivir, Dovato, Kivexa, Triumeq and Trizivir to include new information about use of the products in patients with renal impairment. Furthermore, minor editorial changes have been implemented throughout the Product Information and the lists of local representatives have been updated for all products.                                                                                                                                                                   | 22/07/2021 | 26/08/2021 | SmPC and PL | Patients with a creatinine clearance between 30 and 49 mL/min receiving Combivir/Dovato/ Kivexa/ Triumeq/ Trizivir may experience a 1.6-to 3.3-fold higher lamivudine exposure (AUC) than patients with a creatinine clearance â‰¥ 50 mL/min. There are no safety data from randomized, controlled trials comparing Combivir/Dovato/ Kivexa/ Triumeq/ Trizivir to the individual components in patients with a creatinine clearance between 30 and 49 mL/min who received dose-adjusted lamivudine. In the original lamivudine registrational trials in combination with zidovudine, higher lamivudine exposures were associated with higher rates of haematologic toxicities (neutropenia and anaemia), although discontinuations due to |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|         | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                             |            |            |      | neutropenia or anaemia each occurred in <1% of subjects. Other lamivudine-related adverse events (such as gastro- intestinal and hepatic disorders) may occur. The CHMP considered that, with the exception of Epivir, the previous recommendations to adjust the dose in patients with a sustained creatinine clearance between 30 and 49 mL/min can be removed. Patients with a sustained creatinine clearance between 30 and 49 mL/min who receive Combivir/Dovato/ Kivexa/ Triumeq/ Trizivir should be monitored for lamivudine- related adverse events, notably haematologic toxicities. If new or worsening neutropenia or anaemia develop, a dose adjustment of lamivudine, per lamivudine prescribing information, is indicated, which cannot be achieved with Combivir/Dovato/ Kivexa/ Triumeq/ Trizivir. Combivir/Dovato/ Kivexa/ Triumeq/ Trizivir should be discontinued and the individual components should be used to construct the treatment regimen. The existing dose recommendations for Epivir have been maintained. The CHMP considered the lack of impact on pill burden when the lamivudine dose is adjusted for a monocomponent product and the fact that dose adjustments may be still used for subjects initially treated with lamivudine-containing fixed dose combinations, but requiring dose-adjusted individual components administration for safety reasons. For more information, please refer to the Summary of Product Characteristics.   |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/1989 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. | 24/06/2021 | 26/08/2021 | SmPC | No specific symptoms or signs have been identified following acute overdose with abacavir, zidovudine or                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

|                    | Update of section 4.9 of the SmPC to revise the overdose information. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                      |            |            |                        | lamivudine apart from those listed as adverse reactions.   |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|------------------------------------------------------------|
| IG/1361            | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                | 04/03/2021 | 12/08/2021 | Annex II and PL        |                                                            |
| IG/1333            | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing       | 20/01/2021 | n/a        |                        |                                                            |
| WS/1951            | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation | 03/12/2020 | 12/08/2021 | SmPC and PL            |                                                            |
| IG/1237            | A.1 - Administrative change - Change in the name and/or address of the MAH                                                                                                                                                                   | 11/06/2020 | 12/08/2021 | SmPC, Labelling and PL |                                                            |
| PSUSA/9207/ 201811 | Periodic Safety Update EU Single assessment - lamivudine (HIV infections), lamivudine / zidovudine                                                                                                                                           | 11/07/2019 | n/a        |                        | PRAC Recommendation - maintenance                          |

<div style=\"page-break-after: always\"></div>

|           | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 21/11/2018   | 31/01/2019   | SmPC, Labelling and PL   | T/0094   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|--------------------------|----------|
| IA/0095   | B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer                                                                                                                                                                                                                                                                                                                                                  | 23/11/2018   | n/a          |                          |          |
| IAIN/0093 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                               | 28/09/2018   | 31/01/2019   | SmPC                     |          |
| IG/0923/G | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient | 22/05/2018   | n/a          |                          |          |
| WS/1334/G | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting                                                                                                                                                                                                                                                                                                  | 15/02/2018   | n/a          |                          |          |

<div style=\"page-break-after: always\"></div>

|         | material/intermediate/reagent - Other variation B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                      |            |            |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/1156 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of section 4.5 of the SmPC to add information regarding the interaction between lamivudine and sorbitol based on the results of Study 204857. The Package Leaflet has been updated accordingly. Further, a minor amendment has been implemented throughout the SmPC in order to update the clinical terminology of Pneumocystis carinii pneumonia to Pneumocystis jiroveci pneumonia. In addition, the MAH takes the opportunity to make minor editorial changes, to align the annexes with the QRD template version 10 and to update the contact details of the local representatives in the Package Leaflet. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance | 25/01/2018 | 31/01/2019 | SmPC, Labelling and PL | Study 204857 was undertaken to evaluate the effect of sorbitol on the pharmacokinetics of lamivudine. The study concluded that concomitant use of lamivudine with chronic administration of sorbitol containing medicines may reduce the exposure of lamivudine, possibly resulting in reduced virologic suppression or viral resistance. Co-administration of sorbitol solution (3.2 g, 10.2 g, 13.4 g) with a single 300 mg dose (Adult HIV daily dose) of lamivudine oral solution resulted in dose-dependent decreases of 14%, 32%, and 36% in lamivudine exposure (AUC) and 28%, 52%, and 55% in the Cmax of lamivudine in adults. When possible, avoid chronic co-administration of Zeffix with medicinal products containing sorbitol or other osmotic acting poly-alcohols or monosaccharide alcohols (e.g. xylitol, mannitol, lactitol, maltitol). Consider more frequent monitoring of HIV-1 viral load when chronic co- administration cannot be avoided. |

<div style=\"page-break-after: always\"></div>

| PSUSA/9207/ 201511   | Periodic Safety Update EU Single assessment - lamivudine (HIV infections), lamivudine / zidovudine                                                                                                                                                                                                                                                                                                                                                                                                                                           | 02/09/2016   | n/a        |                        | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                          |
|----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0089              | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                               | 19/07/2016   | 03/03/2017 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                            |
| IG/0688              | B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer                                                                                                                                                                                                                                                                                                                                                  | 19/05/2016   | n/a        |                        |                                                                                                                                                                                                                                                                                                                                            |
| IG/0670/G            | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient | 13/04/2016   | n/a        |                        |                                                                                                                                                                                                                                                                                                                                            |
| WS/0769              | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of section 4.4 of the SmPC in order to revise the wording regarding mitochondrial dysfunction                                                                                                                                                                                                                                                                                           | 01/04/2016   | 03/03/2017 | SmPC and PL            | Nucleos(t)ide analogues may impact mitochondrial function to a variable degree, which is most pronounced with stavudine, didanosine and zidovudine. There have been reports of mitochondrial dysfunction in HIV negative infants exposed in utero and/or postnatally to nucleoside analogues; these have predominantly concerned treatment |

<div style=\"page-break-after: always\"></div>

|           | following assessment of responses to a relevant LEG and after analysis of the final CSR of the Mitochondrial Toxicity in Children (MITOC) Study (WE027/WWE112888). The Package leaflet is updated accordingly. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority   |            |            |             | with regimens containing zidovudine. The main adverse reactions reported are haematological disorders (anaemia, neutropenia) and metabolic disorders (hyperlactatemia, hyperlipasemia). These events have often been transitory. Late onset neurological disorders have been reported rarely (hypertonia, convulsion, abnormal behaviour). Whether such neurological disorders are transient or permanent is currently unknown. These findings should be considered for any child exposed in utero to nucleos(t)ide analogues, that present with severe clinical findings of unknown etiology, particularly neurologic findings. These findings do not affect current national recommendations to use antiretroviral therapy in pregnant women to prevent vertical transmission of HIV.   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/0888/G | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation          | 28/01/2016 | 02/05/2016 | SmPC and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| WS/0755   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of section 5.1 of the SmPC in order to include information regarding the absence of antagonist effects in vitro between the active substances and                                                         | 17/09/2015 | 02/05/2016 | SmPC        | This procedure update section 5.1 of the SmPC in order to include information regarding the absence of antagonist effects in vitro between the active substances and other retrovirals.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

|           | other retrovirals. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                    |            |            |             |              |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------|
| IAIN/0084 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                          | 08/07/2015 | 02/05/2016 | SmPC and PL |              |
| IG/0537/G | This was an application for a group of variations. B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer B.III.2.b - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a | 13/05/2015 | n/a        |             | Member State |
| IG/0552   | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                                                                                                                                                                                        | 08/05/2015 | n/a        |             |              |
| WS/0645   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of section 4.6 of the SmPC to include the WHO guidelines on breastfeeding. The Package                                                                                                                                                                                                             | 23/04/2015 | 02/05/2016 | SmPC and PL |              |

<div style=\"page-break-after: always\"></div>

|           | has been updated accordingly. In addition, the WSA has taken the opportunity to promote consistency across products by updating where relevant (i.e. for Trizivir, Combivir, Lamivudine/Zidovudine ViiV and Triumeq), the pharmacokinetic statements in section 4.6 of the SmPC to reflect the most recently approved wording for the components abacavir and lamivudine (Kivixa EMEA/H/C/581/R/0051 and Epivir EMEA/H/C/107/II/0084). C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   |            |     | Leaflet   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------|
| II/0078   | Submission of the final study report for an observational multi-cohort study on the use and safety of Combivir scored tablets among HIV-infected children and adolescent using the EPPICC data as mentioned in the version 4 of Combivir EU Risk Management Plan (RMP). C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                      | 26/02/2015 | n/a |           |
| WS/0393/G | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.                                                                                                                                                                                                                                                                                                                                                                                                    | 22/05/2014 | n/a |           |

<div style=\"page-break-after: always\"></div>

| This was an application following a worksharing Article 20 of Commission 1234/2008. B.I.a.1.z - Change in the intermediate used in the the active substance B.I.a.1.z - Change in the intermediates used in the active substance A.4 - Administrative change a manufacturer of the manufacture of the active A.7 - Administrative change manufacturing sites B.I.a.2.a - Changes in the AS - Minor change of the AS B.I.a.2.a - Changes in the AS - Minor change of the AS B.I.a.2.a - Changes in the AS - Minor change of the AS B.I.a.3.a - Change in batch ranges) of intermediate compared to the originally B.I.a.3.a - Change in batch ranges) of intermediate compared to the originally   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

| ranges) of intermediate compared to the originally B.I.b.1.b - Change in reagent - Tightening B.I.b.1.z - Change in and/or limits of a reagent B.I.b.1.b - Change in reagent - Tightening B.I.b.1.z - Change in and/or limits of a reagent B.I.b.2.c - Change in Other changes to a which does not have overall quality of the B.I.b.1.z - Change in reagent - Other variation B.I.b.2.c - Change in Other changes to a which does not have overall quality of the B.I.b.1.z - Change in and/or limits of a reagent B.I.b.1.z - Change in and/or limits of a reagent B.I.b.1.z - Change in and/or limits of a reagent B.I.b.1.z - Change in reagent - Other variation B.I.b.2.c - Change in Other changes to a which does not have   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

<!-- image -->

| B.I.b.1.z - Change in reagent - Other variation B.I.b.1.z - Change in reagent - Other variation B.I.b.1.z - Change in and/or limits of a reagent B.I.b.1.z - Change in reagent - Other variation B.I.b.1.z - Change in and/or limits of a reagent B.I.b.1.d - Change in and/or limits of a reagent significant specification an obsolete parameter) B.I.b.1.d - Change in and/or limits of a starting non-significant specification of an obsolete parameter) B.I.b.1.b - Change in and/or limits of a starting specification limits B.I.b.1.z - Change in and/or limits of a starting B.I.b.2.e - Change in - Other changes to a replacement or addition) B.I.b.1.z - Change in intermediate - Other B.I.b.1.z - Change in intermediate - Other B.I.b.1.b - Change in   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

| specification limits B.I.b.1.z - Change in and/or limits of an intermediate B.I.b.1.z - Change in and/or limits of an intermediate B.I.b.1.z - Change in and/or limits of an intermediate B.I.b.1.z - Change in intermediate - Other B.I.b.1.z - Change in intermediate - Other B.I.a.4.z - Change to applied during the manufacture variation B.I.a.4.z - Change to applied during the manufacture variation B.I.a.1.z - Change in starting material/reagent/intermediate variation B.I.a.1.z - Change in starting material/reagent/intermediate variation A.4 - Administrative change and/or address of a manufacturer or supplier of the AS, intermediate used in manufacturer of a novel A.7 - Administrative change manufacturing sites   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

| the AS - Minor change of the AS B.I.a.2.a - Changes in the AS - Minor change of the AS B.I.a.2.a - Changes in the AS - Minor change of the AS B.I.a.3.a - Change in batch ranges) of AS or intermediate increase compared to the size B.I.a.3.a - Change in batch ranges) of AS or intermediate increase compared to the size B.I.a.3.a - Change in batch ranges) of AS or intermediate increase compared to the size B.I.b.1.z - Change in the and/or limits of an AS, material/intermediate/reagent B.I.b.1.z - Change in the and/or limits of an AS, material/intermediate/reagent B.I.b.1.b - Change in the and/or limits of an AS, material/intermediate/reagent specification limits B.I.b.1.z - Change in the   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

| material/intermediate/reagent B.I.b.2.c - Change in starting material/reagent/intermediate changes to a test procedure does not have a significant quality of the AS B.I.b.1.z - Change in and/or limits of an AS, material/intermediate/reagent B.I.b.2.c - Change in starting material/reagent/intermediate changes to a test procedure does not have a significant quality of the AS B.I.b.1.z - Change in and/or limits of an AS, material/intermediate/reagent B.I.b.1.z - Change in and/or limits of an AS, material/intermediate/reagent B.I.b.1.z - Change in and/or limits of an AS, material/intermediate/reagent B.I.b.1.z - Change in and/or limits of an AS, material/intermediate/reagent B.I.b.2.c - Change in starting material/reagent/intermediate changes to a test procedure does not have a significant quality of the AS   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

<!-- image -->

| and/or limits of an AS, material/intermediate/reagent B.I.b.1.z - Change in and/or limits of an AS, material/intermediate/reagent B.I.b.1.z - Change in and/or limits of an AS, material/intermediate/reagent B.I.b.1.z - Change in and/or limits of an AS, material/intermediate/reagent B.I.b.1.z - Change in and/or limits of an AS, material/intermediate/reagent B.I.b.1.d - Change in and/or limits of an AS, material/intermediate/reagent significant specification an obsolete parameter) B.I.b.1.d - Change in and/or limits of an AS, material/intermediate/reagent significant specification an obsolete parameter) B.I.b.1.b - Change in and/or limits of an AS, material/intermediate/reagent specification limits B.I.b.1.b - Change in and/or limits of an AS, material/intermediate/reagent   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

<!-- image -->

| B.I.b.2.e - Change in starting material/reagent/intermediate changes to a test procedure or addition) for the AS material/intermediate B.I.b.1.z - Change in and/or limits of an AS, material/intermediate/reagent B.I.b.1.z - Change in and/or limits of an AS, material/intermediate/reagent B.I.b.1.b - Change in and/or limits of an AS, material/intermediate/reagent specification limits B.I.b.1.z - Change in and/or limits of an AS, material/intermediate/reagent B.I.b.1.z - Change in and/or limits of an AS, material/intermediate/reagent B.I.b.1.z - Change in and/or limits of an AS, material/intermediate/reagent B.I.b.1.z - Change in and/or limits of an AS, material/intermediate/reagent B.I.b.1.z - Change in and/or limits of an AS, material/intermediate/reagent B.I.a.4.z - Change to   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|         | variation B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation                                                                                                                                                                                                                                                                                                                                                                                           |            |            |             |                                                                                                                                                                                                                                                                                                                                                                              |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/0438 | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                                                                                                                                                                                                                                                                                                                 | 16/05/2014 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                              |
| WS/0544 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of section 4.4 of the SmPC with a revised wording on the risk of transmission as requested by the CHMP. The PL has been updated accordingly. In addition, minor corrections are made to translations and an editorial change is implemented in Trizivir PL. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation | 25/04/2014 | 20/04/2015 | SmPC and PL | The warnings in product information regarding the risk of transmission have been updated as requested by the CHMP in a class labelling request adopted in December 2013. Minor corrections are made to translations of Combivir SmPC in Danish and PL in Finnish and Slovenian, Celsentri SmPC and PL in Finnish and Hungarian, Telzir PL in Finnish, Tivicay SmPC in Dutch. |
| N/0074  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                | 27/11/2013 | 20/04/2015 | PL          |                                                                                                                                                                                                                                                                                                                                                                              |
| IG/0348 | B.III.1.a.4 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Deletion of certificates (in case multiple certificates exist per material)                                                                                                                                                                                                                                                                                                   | 21/08/2013 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

| IG/0342   | B.III.1.a.2 - Submission of a new or updated Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 21/08/2013   | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/0361   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of sections 4.4 and 4.5 of the SmPC in order to reflect a potential drug-drug interaction between lamivudine and cladribine. This labelling update has been assessed via a separate Type II variation procedure (Zeffix; EMEA/H/C/242/II/53) with confirmation that the change should also be implemented for other lamivudine containing ViiV marketed HIV products as listed above. The Package Leaflet was updated accordingly and an error in Trizivir SmPC in one of the sub-headings in the tabular summary of interaction information was also amended. C.I.3.a - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under A 45/46, or amendments to reflect a Core SPC - Changes with NO new additional data are submitted by the MAH | 25/04/2013   | 27/05/2013 | SmPC and PL | The drug-drug interaction between lamivudine and cladribine (CdA) was assessed in a type II variation of Zeffix (EMEA/H/C/242/II/53) based on a publication by Chtioui et al (Concomitant treatment with lamivudine renders cladribine inactive by inhibition of its phosphorylation. Br.J.Haematology. 2008; 144: 136-137). This article described a patient with chronic lymphoid leukaemia who was treated with CdA and Zeffix. No decrease of the peripheral blood lymphocyte count was observed after the first cycle of CdA. Zeffix was discontinued and the lymphocyte count decreased following the second and third cycles of CdA. The authors suspected a potential interaction based on intracellular phosphorylation when both medicines are administered concomitantly. In addition, an in vitro study was carried out using peripheral blood mononuclear cells isolated from a healthy volunteer. This in vitro study showed that phosphorylated CdA levels were decreased with increasing 3TC concentrations. |
| IG/0295   | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 29/04/2013   | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

| WS/0338   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of sections 4.4 and 4.8 of the SmPC in order to expand existing warning about immune reactivation syndrome with information on autoimmune disorders. The Package Leaflet is updated accordingly. In addition, the list of local representatives was updated in the Package Leaflet. Furthermore, the product information is being brought in line with the latest QRD template version 8.3. C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data   | 21/02/2013   | 26/03/2013   | SmPC, Annex II, Labelling and PL   | The review performed by the Marketing Authorisation Holder identified 75 cases of different autoimmune disorders occurring in the setting of immune reconstitution. These included Basedow ' s/Graves ' disease, systemic lupus erythematosus, sarcoidosis, rheumatoid arthritis, polymyositis, Guillain-BarrÃ© syndrome, Still ' s syndrome and myasthenia gravis. Cases involving zidovudine, lamivudine, abacavir and fosamprenavir were identified. These disorders all developed when CD4 count was increased or increasing and viral load undetectable. The autoimmune disorders resolved (or improved) spontaneously or with specific therapy and while Anti-Retroviral Therapy was continued. Most of cases had a relatively late onset following Anti-Retroviral Therapy initiation except cases of Guillain-BarrÃ© syndrome and adult onset Still ' s disease. The time to onset ranged from 2 weeks to 37 months. While it was recognised that the number of cases is small, the long and variable time to onset probably causes underreporting of such adverse reactions and therefore little is known on the exact pathogenesis and the risk factors. The CHMP agreed that information about autoimmune disorders occurring in the context of immune reconstitution should be reflected in the product   |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0066/G | This was an application for a group of variations. B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch- release, batch control, primary and secondary packaging, for non-sterile medicinal products                                                                                                                                                                                                                                                                                                                                                                                                              | 25/02/2013   | n/a          |                                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

|           | - Change in the batch size (including batch ranges) of the finished product - Up to 10-fold to the currently approved batch size                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |            |     | B.II.b.4.a size compared   |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----------------------------|
| IA/0068   | B.II.b.3.a - Change in the manufacturing process of the finished product - Minor change in the manufacturing process of an immediate release solid oral dosage form or oral solutions                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 05/02/2013 | n/a |                            |
| IA/0067/G | This was an application for a group of variations. B.II.b.3.a - Change in the manufacturing process of the finished product - Minor change in the manufacturing process of an immediate release solid oral dosage form or oral solutions B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.1.c - Change in the specification parameters and/or limits of the finished product - Addition of a new specification parameter to the specification with its corresponding test method B.II.d.1.d - Change in the specification parameters and/or limits of the finished product - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter | 20/12/2012 | n/a |                            |
| IG/0205   | B.II.b.3.a - Change in the manufacturing process of the finished product - Minor change in the manufacturing process of an immediate release solid oral dosage form or oral solutions                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 30/07/2012 | n/a |                            |

<div style=\"page-break-after: always\"></div>

| IG/0191/G   | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS A.7 - Administrative change - Deletion of manufacturing sites B.III.1.a.2 - Submission of a new or updated Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer                                                                                                                                                                                                                                                                       | 25/06/2012   | n/a        |          |                                                                                                                            |
|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------|----------------------------------------------------------------------------------------------------------------------------|
| WS/0163     | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Introduction of a new Detailed Description of the Pharmacovigilance System (DDPS), following the transfer of the marketing authorisation/scientific opinion from GSK to ViiV Healthcare Ltd. This DDPS had previously been assessed for another product of the same MAH/SOH. Annex IIB of Epivir, Kivexa, Lamivudine ViiV and Trizivir have consequently been updated in line with the new QRD template wording for the DDPS. In addition the MAH corrected a minor mistake in the French Annex for Epivir. C.I.8.b - Introduction of a new Pharmacovigilance system - which has been assessed by the relevant | 21/06/2012   | 21/06/2012 | Annex II | Update of the Detailed Description of the Pharmacovigilance System (DDPS) to ViiV Healthcare Ltd version 4 dated May 2012. |

<div style=\"page-break-after: always\"></div>

|         | NCA/EMA for another product of the same MAH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |            |            |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0059 | Update of sections 4.4, 4.5, 4.6 and 5.1 of the SmPC in fulfilment of commitments (FUM 034) related to all antiretroviral agents containing lamivudine based on clinical experience gained on the use of lamivudine during pregnancy and on new information available on interactions. The PL was updated accordingly. The MAH took this opportunity to introduce minor corrections in section 4.2, 4.4 and in Annex IIIA, and to update the local representatives details in the PL. C.I.3.b - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under Article 45/46, or amendments to reflect a Core SPC - Change(s) with new additional data submitted by the | 17/03/2011 | 02/05/2011 | SmPC, Annex II, Labelling and PL | A warning statement has been added in section 4.4 that Combivir should not be used with other products containing lamivudine or emtricitabine. Section 4.6 has been revised to reflect the clinical data provided by the Antiretroviral Pregnancy Registry (APR) and to align it with other antiretroviral products. Section 4.5 has been updated with new information on interaction and restructured in line with the tabular format described in the HIV guideline. The information on carcinogenic risk in section 5.3 was amended in line with the revised section 4.6. Minor corrections were introduced in sections 4.2, 4.4 and in Annex II and IIIA. The PL was updated accordingly as well as the local representatives details. |
| II/0060 | Update of section 4.8 of the SmPC to add 'angioedema' as a new adverse event in fulfilment of PSU033 (covering period 01.12.06 - 30.11.09 and concerning all lamivudine-containing products). The PL has been revised accordingly and aligned to QRD template. In addition the MAH took this opportunity to update the contact details of local representatives, the EMA website address and some minor mistakes in Annex II, Labelling and PL. C.I.3.b - Implementation of change(s) requested                                                                                                                                                                                                                                               | 23/09/2010 | 03/11/2010 | SmPC, Annex II, Labelling and PL | Section 4.8 of the SmPC has been amended with the addition of the new adverse event \"angioedema\" and the calculation of its frequency (rare). PL was modified accordingly. Moreover minor corrections were introduced to amend the local representatives list in the PL, the EMA website address in Annex II and some mistakes in Annex IIIA and PL.                                                                                                                                                                                                                                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

|         | following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under Article 45/46, or amendments to reflect a Core SPC - Change(s) with new additional data submitted by the MAH                                                                                                                                                                                                                                      |            |            |                        |                                                                                                                                                                                                                                                                                                                                                                                                 |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| N/0058  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                 | 30/07/2010 | n/a        | PL                     |                                                                                                                                                                                                                                                                                                                                                                                                 |
| T/0057  | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                              | 29/03/2010 | 10/05/2010 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                 |
| II/0056 | Update of the Detailed Description of the Pharmacovigilance System (DDPS) including change of the Qualified Person for Pharmacovigilance (QPPV). Consequently, Annex II has been updated with the new version number. Update of DDPS (Pharmacovigilance)                                                                                                                                                                                         | 17/12/2009 | 25/01/2010 | Annex II               | The DDPS has been updated (version 7.2) to reflect the change of the QPPV as well as to notify other changes to the DDPS performed since the last approved version. Consequently, Annex II has been updated using the standard text including the new version number of the agreed DDPS. The CHMP considers that the Pharmacovigilance System as described by the MAH fulfils the requirements. |
| II/0055 | Update of the Detailed Description of Pharmacovigilance Systems (DDPS) in order to include the change of the Qualified Person for Pharmacovigilance (QPPV). In addition, the Marketing Authorisation Holder (MAH) took the opportunity to notify other minor changes to the DDPS performed since the last approved version. Consequently, Annex II has been updated using the standard text including the new version number of the agreed DDPS. | 19/02/2009 | 02/04/2009 | Annex II               | The DDPS has been updated (version 6.2) to reflect the change of the Qualified Person for Pharmacovigilance (QPPV) as well as to notify other changes to the DDPS performed since the last approved version. Consequently, Annex II has been updated using the standard text including the new version number of the agreed DDPS.                                                               |

<div style=\"page-break-after: always\"></div>

|         | Update of DDPS (Pharmacovigilance)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |            |            |                           |                                                                                                                                                                                                                                                                                                                                                                                                              |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|---------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0051 | To update sections 4.2 \"Posology and method of administration\" and 5.2 \"Pharmacokinetic properties\" of the Summary of Product Characteristics relating to administration of crushed tablets with food and liquid further to CHMP request following assessment of the FUM 28 in February 2008. Section 3 of the Package Leaflet was updated accordingly. The MAH also took the opportunity to update section 6 of the Package Leaflet with new contact details for the local representative in Latvia. In addition, the Labelling has been updated with the inclusion of Braille. Update of Summary of Product Characteristics, | 24/07/2008 | 16/09/2008 | SmPC, Labelling and PL    | Studies concerning the administration of crushed tablets with a small amount of semi-solid food or liquid show that the tablets can be crushed and then administered with small amount of semi-solid food or liquid without pharmaceutical quality impact. This information is useful for the treatment of paediatric patients who cannot swallow tablets and also for adults in difficulties in swallowing. |
| IA/0054 | IA_15_a_Submission of Ph. Eur. certificate for active substance - approved manufacturer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 29/07/2008 | n/a        |                           |                                                                                                                                                                                                                                                                                                                                                                                                              |
| IA/0053 | IA_15_a_Submission of Ph. Eur. certificate for active substance - approved manufacturer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 29/07/2008 | n/a        |                           |                                                                                                                                                                                                                                                                                                                                                                                                              |
| IA/0052 | IA_15_a_Submission of Ph. Eur. certificate for active substance - approved manufacturer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 29/07/2008 | n/a        |                           |                                                                                                                                                                                                                                                                                                                                                                                                              |
| R/0049  | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 13/12/2007 | 13/02/2008 | SmPC, Annex II, Labelling | Based on the review of the available information the CHMP is of the opinion that the quality, the safety and the efficacy                                                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |            |            | and PL      | of this medicinal product continues to be adequately and sufficiently demonstrated and therefore considers that the benefit/risk profile of Combivir continues to be favorable. The renewal was granted with unlimited validity.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0050 | Change(s) to the manufacturing process for the active substance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 24/01/2008 | 29/01/2008 |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| II/0044 | To update sections 4.4 \"Special warnings and precautions for use\" and 4.5 \"Interaction with other medicinal products and other forms of interaction\" of the Summary of Product Characteristics (SPC) concerning interactions relevant to zidovudine: clarithromycin and ribavirin. The CHMP took the opportunity of this variation to harmonise the information on interactions for all zidovudine containing products. Section 2 of the Package Leaflet (PL) was updated accordingly. Update of Summary of Product Characteristics and Package Leaflet | 18/10/2007 | 23/11/2007 | SmPC and PL | Following the European Mutual Recognition renewal application for zidovudine (Retrovir), the Summary of Products Characteristics (SPC) and the Package Leaflet (PL) of Retrovir were modified as regards the interaction with ribavirin and clarithromycin. The interaction between ribavirin and zidovudine was removed and a statement referring that clarithromycin tablets reduce the absorption of zidovudine was introduced. The MAH has submitted type II variation applications for the other medicinal products containing zidovudine (Combivir, Lamivudine/Zidovudine GSK and Trizivir) to update the information to be in line with the Retrovir SPC and PL. Furthermore, there is now a lot of evidence from clinical trials and from literature that concomitant use of zidovudine and ribavirin is associated with a greater risk of anaemia. The consensus conference on the treatment of HCV/HIV co-infected patients already recommended that the use of zidovudine should be avoided due to an excess risk of anaemia. The CHMP took the opportunity of this variation to check the consistency concerning the information on interactions relevant to zidovudine and to harmonise the product |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                                                                                                                                                                                    |            |            |                                  | information of the products containing zidovudine.                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0043 | Update of summary of product characteristics, annex II, labelling and package leaflet Extension of indication to paediatric patients and replacement of film coated tablets by scored film coated tablets. Furthermore, the MAH took the opportunity of this variation to split the outer carton and bottle label. | 20/09/2007 | 13/11/2007 | SmPC, Annex II, Labelling and PL | This will refer to the scientific discussion of this assessment report.                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| II/0048 | To update section 5.1 of the SPC concerning the emergence of M184V mutation following CHMP request dated 18 October 2006. Update of Summary of Product Characteristics                                                                                                                                             | 19/07/2007 | 03/09/2007 | SmPC                             | The MAH submitted this type II variation II/48 to update section 5.1 of the SPC by adding information to discourage the maintenance of lamivudine in presence of M184V mutation when other active NRTIs are available following CHMP request dated 18 October 2006. This request was driven by the renewal of the Marketing Authorisation (R/52) for Epivir (lamivudine), which is another NRTIs indicated in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus (HIV) infection. |
| II/0042 | Quality changes                                                                                                                                                                                                                                                                                                    | 22/02/2007 | 01/03/2007 |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| IA/0047 | IA_06_a_Change in ATC code: Medicinal products for human use                                                                                                                                                                                                                                                       | 27/02/2007 | n/a        | SmPC                             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| IA/0046 | IA_04_Change in name and/or address of a manuf. of the active substance (no Ph. Eur. cert. avail.)                                                                                                                                                                                                                 | 20/02/2007 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

| II/0041   | Update of section 4.4 and section 4.8 of the SPC and section 2 of the PL to implement the class labelling text on osteonecrosis, agreed by the CHMP in September 2006. In addition the MAH completed the list of local representatives in the PL to include the two new EU Member States (Bulgaria and Romania) and changed the format according to the latest EMEA/QRD template. Update of Summary of Product Characteristics, Labelling and Package Leaflet   | 14/12/2006   | 26/01/2007   | SmPC, Annex II, Labelling and PL   | Cases of osteonecrosis (death of the bone tissue resulting from an insufficient blood supply) have been reported in HIV-infected patients since the end of the 80's. Although the cause of this disease could be due to multi factors (including the use of corticosteroids, alcohol consumption, severe immunosuppression, higher body mass index) it has occurred specially in patients with HIV advanced disease and/or in patients with long term use of combination antiretroviral therapy (CART). Further to the review of all available data the CHMP agreed that this information should now be included in the SPC and PL of all antiretroviral medicinal products. Patients should be warned to seek medical advice in case they experience joint stiffness, aches and pain especially of the hip, knee and shoulder or if they experienced any difficulty in movement.   |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0039   | IB_17_a_Change in re-test period of the active substance                                                                                                                                                                                                                                                                                                                                                                                                        | 09/08/2006   | n/a          |                                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| IA/0040   | IA_11_a_Change in batch size of active substance or intermediate - up to 10-fold                                                                                                                                                                                                                                                                                                                                                                                | 26/07/2006   | n/a          |                                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| IA/0038   | IA_08_b_02_Change in BR/QC testing - repl./add. manuf. responsible for BR - incl. BC/testing                                                                                                                                                                                                                                                                                                                                                                    | 19/07/2006   | n/a          | Annex II and PL                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| IA/0037   | IA_07_a_Replacement/add. of manufacturing site: Secondary packaging site IA_07_b_01_Replacement/add. of manufacturing site: Primary packaging site - Solid forms                                                                                                                                                                                                                                                                                                | 19/07/2006   | n/a          |                                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| IB/0034   | IB_14_b_Change in manuf. of active substance without Ph. Eur. certificate - new manufacturer                                                                                                                                                                                                                                                                                                                                                                    | 06/01/2006   | n/a          |                                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

| IB/0035   | IB_14_b_Change in manuf. of active substance without Ph. Eur. certificate - new manufacturer                                                                                                                                                                                                     | 05/01/2006   | n/a        |                 |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------|
| IA/0036   | IA_11_a_Change in batch size of active substance or intermediate - up to 10-fold                                                                                                                                                                                                                 | 08/12/2005   | n/a        |                 |
| IA/0033   | IA_15_a_Submission of Ph. Eur. certificate for active substance - approved manufacturer                                                                                                                                                                                                          | 14/09/2005   | n/a        |                 |
| IA/0032   | IA_15_a_Submission of Ph. Eur. certificate for active substance - approved manufacturer                                                                                                                                                                                                          | 14/06/2005   | n/a        |                 |
| II/0031   | Update of Summary of Product Characteristics and Package Leaflet                                                                                                                                                                                                                                 | 18/11/2004   | 05/01/2005 | SmPC and PL     |
| IB/0030   | IB_37_b_Change in the specification of the finished product - add. of new test parameter                                                                                                                                                                                                         | 07/12/2004   | n/a        |                 |
| IA/0029   | IA_11_a_Change in batch size of active substance or intermediate - up to 10-fold                                                                                                                                                                                                                 | 03/09/2004   | n/a        |                 |
| IA/0028   | IA_05_Change in the name and/or address of a manufacturer of the finished product                                                                                                                                                                                                                | 29/07/2004   | n/a        | Annex II and PL |
| II/0026   | Update of the section 4.4 (Special warnings and special precaution for use) of the Summary of Product Characteristics (SPC) and section 2 of the Package Leaflet (PL) under subheading \"Pregnancy\" , to implement the class labelling for nucleoside/nucleotide reverse transcriptase inhibitors | 24/03/2004   | 26/05/2004 | SmPC and PL     |

<div style=\"page-break-after: always\"></div>

|         | (NRTIs) regarding mitochondrial toxicity in children with in utero and post-natal exposure, as adopted by the CPMP in November 2003 Update of Summary of Product Characteristics and Package Leaflet                                                                                                                                                                                                                                                                                                                                                                                                                              |            |            |             |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|
| IA/0027 | IA_15_a_Submission of Ph. Eur. certificate for active substance - approved manufacturer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 09/03/2004 | n/a        |             |
| IB/0025 | IB_10_Minor change in the manufacturing process of the active substance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 10/02/2004 | n/a        |             |
| II/0021 | Update of the section 4.4 \"Special warnings and special precautions of use\" of the Summary of Product Characteristics (SPC) to implement the class labelling on liver impairment adopted by the CPMP for all anti-retroviral medicinal products in April 2003. The section 2 of PL is amended accordingly. Furthermore, the MAH has taken this opportunity to update the PL in section 4 to revise the wording on lipodystrophy as recommended by the CPMP in March 2003 and in section 6 to update the telephone number of the local representative in Germany. Update of Summary of Product Characteristics and Package Leaflet | 20/11/2003 | 05/02/2004 | SmPC and PL |
| II/0023 | Update of the section 5.3 \" Preclincal safety data\" of the Summary of Prduict Characteristics (SPC) to illustrate the results of a cohort pilot study showing                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 25/09/2003 | 14/01/2004 | SmPC        |

<div style=\"page-break-after: always\"></div>

|         | zidovudine may be incorporated into leucocyte of Summary of Product Characteristics                                                                                                                                                                                                                                              |            |            |                       | that DNA. Update   |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|--------------------|
| II/0022 | Update of section 5.1 \"Pharmacodynamic properties\" of the Summary of Product Characteristics (SPC) to characterise the role of a \"fixed combination\" product based on resistance data, as requested by the CPMP further to the opinion on the first five year renewal of the Marketing Authorisation. of Product Characteristics | 25/09/2003 | 14/01/2004 | SmPC                  | Update of Summary  |
| IA/0024 | 15a_Change in IPCs applied during the manufacture of the product                                                                                                                                                                                                                                                                 | 20/10/2003 | n/a        |                       |                    |
| I/0020  | 24_Change in test procedure of active substance                                                                                                                                                                                                                                                                                  | 05/08/2003 | 20/08/2003 |                       |                    |
| I/0018  | 34b_Manufacturing process for PhEur components verified by certificate of suitability from PhEur                                                                                                                                                                                                                                 | 08/08/2003 | 20/08/2003 |                       |                    |
| I/0019  | 01_Withdrawal of the manufacturing authorisation for a site of manufacture                                                                                                                                                                                                                                                       | 18/07/2003 | 22/07/2003 |                       |                    |
| R/0016  | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                          | 19/03/2003 | 11/06/2003 | SmPC, Annex II and PL |                    |
| I/0015  | 11_Change in or addition of manufacturer(s) of active substance                                                                                                                                                                                                                                                                  | 23/08/2002 | 29/08/2002 |                       |                    |

<div style=\"page-break-after: always\"></div>

| II/0012   | To update the Summary of Product Characteristics (SPC) section 5.1 ( ' Pharmacodynamic Properties ' ) relating to the use of lamivudine and zidovudine as part of HAART and relating to an update of virological information. Furthermore, to update section 4.8 ( ' Undesirable Effects ' ) to include pure red cell aplasia, aplastic anaemia and hepatitis and to reflect the frequencies of the adverse drug reactions in accordance with the SPC guideline. Also, to update section 4.4 ( ' Special warnings and special precautions ' ) to reflect the class labelling statement for nucleoside analogues regarding lactic acidosis as revised by the CPMP. The relevant sections of the package leaflet have been amended accordingly. Furthermore, some minor changes have been incorporated in the SPC and Package Leaflet, in order to bring the text in line with the latest QRD/ EMEA templates. In addition, the list of the Local Representatives has been updated. Update of Summary of Product Characteristics and   | 30/05/2002   | 22/08/2002   | SmPC and PL   |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|---------------|
| I/0014    | 12a_Change in specification of starting material/intermediate used in manuf. of the active substance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 08/05/2002   | 15/05/2002   |               |
| I/0013    | 15_Minor changes in manufacture of the medicinal product 12a_Change in specification of starting material/intermediate used in manuf. of the active                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 05/03/2002   | 13/03/2002   |               |

<div style=\"page-break-after: always\"></div>

|         | substance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |            |            |                        |                 |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------|
| II/0011 | The Marketing Authorisation Holder applied for an update of the Summary of Product Characteristics, (sections 4.4 ' Special warnings and special precautions for use ' , 4.5 ' Interactions ' and 4.8 ' Undesirable effects ' , and as a consequence an update of the Package Leaflet). Furthermore, the MAH proposed some minor changes in the SPC, Labelling and Package Leaflet in order to bring the text in line with the latest QRD/ EMEA templates. Update of Summary of Product Characteristics and | 29/03/2001 | 31/07/2001 | SmPC, Labelling and PL | Package Leaflet |
| II/0010 | The Marketing Authorisation Holder applied for an update of the Summary of Product Characteristics (section ' Undesirable effects ' and as a consequence an update of the Package Leaflet). Furthermore, the MAH proposed some minor changes in the SPC, Labelling and Package Leaflet in order to bring the text in line with the latest QRD/ EMEA templates. Update of Summary of Product Characteristics and Package Leaflet                                                                             | 28/08/2000 | 27/12/2000 | SmPC, Labelling and PL |                 |
| I/0009  | 12_Minor change of manufacturing process of the active substance 11b_Change in supplier of an intermediate compound used in manufacture of the active substance                                                                                                                                                                                                                                                                                                                                             | 20/10/1999 | 20/12/1999 | Labelling              |                 |

<div style=\"page-break-after: always\"></div>

| I/0008   | 11b_Change in supplier of an intermediate compound used in manufacture of the active substance       | 20/10/1999   | 20/12/1999   |                        |           |
|----------|------------------------------------------------------------------------------------------------------|--------------|--------------|------------------------|-----------|
| I/0007   | 11b_Change in supplier of an intermediate compound used in manufacture of the active                 | 20/10/1999   | 20/12/1999   |                        | substance |
| II/0006  | Update of Summary of Product Characteristics and Package Leaflet                                     | 23/06/1999   | 16/11/1999   | SmPC, Labelling and PL |           |
| I/0005   | 12a_Change in specification of starting material/intermediate used in manuf. of the active substance | 25/05/1999   | 03/06/1999   |                        |           |
| I/0004   | 11_Change in or addition of manufacturer(s) of active substance                                      | 19/08/1998   | n/a          |                        |           |
| I/0003   | 13_Batch size of active substance                                                                    | 19/08/1998   | n/a          |                        |           |
| I/0002   | 11_Change in or addition of manufacturer(s) of active substance                                      | 19/08/1998   | n/a          |                        |           |
| N/0001   | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)     | 12/06/1998   | 17/08/1998   | Labelling and PL       |           |